Thus, differences in pharmacokinetics might help explain why the anti-inflammatory activity of rosiglitazone involves activation of PPAR-γ signaling in macrophages (22), whereas 5-ASA activated PPAR-γ signaling in the colonic epithelium to ameliorate DSS-induced colitis. Here, PPARG is linked to colitis.